Dr. Gibson is a Professor at the University of British Columbia on the Okanagan Campus. She is an experimental scientist who studies how the gut microbiome and immune system develop in response to environmental cues such as diet, breast milk, and agriculture practices.
One of the major areas in her research lab is focused on inflammatory bowel disease (IBD). Dr. Gibson has developed novel live biotherapeutics, which are genetically engineered bacteria that are modified to enhance their healing effects to help treat IBD, along with other comorbidities. Dr. Gibson is the current CSO of Melius MicroBiomics Inc., a company she has co-founded to bring these live biotherapeutics to the market.
Current Positions
- Board of Directors for Crohn’s and Colitis Canada
- Co-Chair for the Crohn’s and Colitis Canada Scientific and Medical Advisory Council
- Member of the Canadian Association of Gastroenterology WomenCAN
- Canadian Children Inflammatory Bowel Disease Network (CIDsCaNN!) Basic & Translational Research Committee
- Canadian Scientific Board member for BioCodex Microbiota International Foundation
Awards
- NSERC Early Career Scholar
- UBC Killam Tesearch Scholar
- Canadian Association of Gastroenterology 2018 Young Investigator Award
- CIHR of Nutrition, Metabolism, and Diabetes Community- New Investigator Partnership Prize
- International Society for the Study of Fatty Acids & Lipids